Survodutide GLP-1 receptor dual agonist to be assessed in three global Phase III studies for obesity
Boehringer Ingelheim will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational Phase III studies for...
top of page
Browse by category
Search
Browse by tag
bottom of page